CALIDI BIOTHERAPEUTICS - Key Persons

Job Titles:

• Chief Financial Officer
• Member of the Nominating and Corporate Governance Committee
• Board Member - Appointed October 2023
• CEO of FIT Advisors

Alan R. Stewart serves as Chief Financial Officer bringing a strong background in mergers, acquisitions and corporate finance to the company. Prior to joining SoundThinking, Stewart served as Vanaging Director of RA Capital Advisors, LLC, a private investment bank specializing in mergers and acquisitions, private financings and restructurings. From 2004 to 2014, he served as Chief Financial Officer and then Chief Development Officer of Epsilon Systems Solutions, Inc. Since 2008, Mr. Stewart has served as CEO of FIT Advisors, LLC, a boutique consulting firm that offers temporary CFO services and served clients from start-up ventures to large private companies in vertical industries spanning government contracting, software, retail, healthcare IT, banking and Internet applications. Stewart was selected as San Diego Business Journal's CFO of the Year in 2007 and again in 2013. Both awards were in the large private business category. He was also selected as ACG's Advisor of the Year in 2017 for transactions greater than $25M. In 2021, he was one of three finalists for CFO of the year in emerging public company category by San Francisco Business Journal. In 2023, he was selected as one of the top 25 CFO's in San Francisco by Financeandinvesting.com and as one of the top 10 inspiring CFOs nationwide by C-Level Focus. Prior to his business career, Stewart served over ten years as a submarine nuclear engineer in the United States Navy. He received his B.S. in Oceanography, with distinction, from the U.S. Naval Academy and his M.B.A. from Harvard Business School.

Job Titles:

• Chairman of the Board of Directors
• Chief Executive Officer
• Chairman of the Board - Appointed April 2018 ( and Board Member since August 2015 )

Allan Camaisa co-founded Calidi Biotherapeutics in 2014 and has served as CEO and Chairman of the Board since 2018. He was an early investor in Calidi, and determined to bring a cure for difficult-to-treat cancers to market after losing his own father to cancer. Allan has nearly a decade of experience in oncology and has successfully guided the clinical and preclinical development of Calidi's NeuroNova and SuperNova platforms. Allan has led multiple financing rounds steering the company to a public listing, while successfully negotiating license agreements with pharmaceutical companies, California Institute of Regenerative Medicine (CIRM) grants, and National Institute of Health collaborations. Previously, Allan was the CEO and Chairman of Parallel6, Inc., a digital mobile/cloud software platform for managing pharmaceutical clinical trials. In 2005, Allan founded Anakam, Inc., a software security company focused on healthcare, which safeguarded digital medical records through a platform that delivered government-level multifactor authentication and security. Prior to Anakam, Allan founded High Technology Solutions (HTS), a software systems integrator that he grew from two people to more than 500 employees and $50 million in revenue. Before entering business, Allan served eight years as a surface warfare officer in the United States Navy, graduating from the United States Naval Academy and the prestigious Owners Management Program at Harvard Business School. Allan Camaisa serves as Chairman of the Board of Directors and has been the CEO of Calidi Biotherapeutics since November 2017. Allan was an early investor in Calidi, and determined to bring a cure for difficult-to-treat cancers to market after losing his own father to cancer. As Chairman and CEO, he has successfully led a $20M early-stage Series A round and has been actively involved in recruiting key Board Members and leading MD's and PhD's to the Company's Scientific Advisory Board. Allan's background includes leading the Calidi Bio team in successful license negotiations with large pharmaceutical firms, and signing a collaboration agreement with the National Institutes of Health. Previously, Mr. Camaisa held the titles of CEO and Chairman at Parallel6, Inc., a digital mobile/cloud software platform for managing pharmaceutical patient clinical trials, which sold to PRA Health Sciences in 2017. In 2005, Allan founded and served as CEO at a software security company for managing digital access to medical records: Anakam, Inc., which sold a global license to the Veterans Affairs administration, and other clients including the Center for Medicare and Medicaid (CMS), before being acquired by Equifax in 2010 and receiving an Inc. 500 award. Prior, Mr. Camaisa founded and served as CEO at High Technology Solutions, a software systems integrator, which he grew from two to 500 employees and $50 million in revenue between 1992 and 2003. HTS received the Inc. 500 award for three consecutive years in a row. His accomplishments as a serial startup-bootstrapper, tech entrepreneur, and investor, further include four successful exits sold to publicly-traded Fortune 1000 companies, authorship of seven US patents, and an Ernst & Young Entrepreneur of the Year award. Before beginning his career in business, Mr. Camaisa served eight years as a surface warfare officer in the US Navy. He is a graduate of both the US Naval Academy and the Owner/President Management program at Harvard Business School.

Job Titles:

• Senior Vice President of Technical Operations

Dr. Patel has over 18 years of global biopharma and biotech leadership experience, providing strategic guidance throughout the entire biologic product life cycle. Dr. Patel is responsible for critical oversight of Global Manufacturing, Quality, and Supply Chain to produce Clinical and Commercial therapies utilizing Calidi's innovative cell-based delivery of oncolytic virus. Over the course of his career, he has led the development of over fifteen INDs, two commercial product approvals, and numerous PAS submissions. He was most recently the Senior Director of Product Development at Emergent BioSolutions (formerly PaxVax, Inc., prior to acquisition), where he successfully built and directed cross-functional teams working on numerous technology platforms. Dr. Patel has served on several in-license, out license, and mergers and acquisition deals. Dr. Patel's work at Emergent included extensive experience with a wide range of biologics, including viral vectors, virus-like particles, nanoparticle formulations, and bacterial products. He served as an Operations excellence council member. Prior to Emergent, Dr. Patel led the technical development of oral insulin delivery technology at Ansun Biopharma and cell transplantation therapy for patients with diabetes at MicroIslet. He currently serves as a member of the UCI Customer Experience Advisory Board, and the global Operational Excellence Council, and frequently gives back to the scientific community by participating in NIH review panels. Dr. Patel received Ph.D. in Engineering/Nanotechnology and MS in Chemical Engineering from Louisiana Tech University, Louisiana specializing in using nanotechnology tools for enzyme and DNA encapsulation and delivery funded by a NASA grant. He has Bachelors of Engineering in Chemical from Poona University, India.

Job Titles:

• Chief Financial Officer
• Financial Executive

Mr. Jackson is a financial executive with over 25 years of corporate finance experience with success in publicly traded companies and venture capital backed startups. Mr. Jackson most recently served as Chief Financial Officer of Eterna Therapeutics Inc. from May 2022 to May 2023. Prior to his position at Eterna Therapeutics, Mr. Jackson served as the Chief Financial Officer of Ra Medical Systems, Inc. from April 2018 until May 2022, and as its Interim Chief Executive Officer from August 2019 to March 2020. From October 2016 to April 2018, he was Chief Financial Officer for AltheaDx, Inc, a molecular diagnostics company specializing in precision medicine. From March 2014 to March 2016, Mr. Jackson held senior financial positions, including Chief Financial Officer, at Celladon Corporation, a publicly traded, clinical stage biotechnology company. From April 2013 to March 2014, he held senior financial positions at Sapphire Energy, an industrial biotechnology company. Mr. Jackson received a MSBA in Finance in December 2006 from San Diego State University and a BSB in Accounting in June 1992 from the University of Minnesota. He is a certified public accountant (inactive).

Job Titles:

• Chief Scientific Officer
• Senior Vice President, Global Head of Research and Development at Calidi

Dr. Santidrian has been the Senior Vice President, Global Head of Research and Development at Calidi since September 2021. He joined Calidi in 2015 as Associate Director. Dr. Santidrian is an accomplished scientist with over 20 years of experience in anti-cancer translational research. Dr. Santidrian has focused his scientific career on developing superior cancer drugs, and on biological drugs to improve human health. He has extensive supervisory and management experience and excellent skills in biotech business development, communication, and collaboration. From March 2008 to September 2015, Dr. Santidrian led translational studies at The Scripps Research Institute for several small molecule and biologic drugs to treat breast cancer metastasis. Dr. Santidrian worked closely on the translational cancer studies for the development of ACADRA to treat Chronic lymphocytic leukemia (CLL) at university of Barcelona (Spain). Dr. Santidrian is the recipient of a fellowship from August Pi I Sunyer Foundation, the Ministry of Science and Education (Spain) and Susan G. Komen Breast cancer foundation. Dr. Santidrian received degree in Pharmacy by University of Barcelona in 2001 and Ph.D. in biomedicine, specializing in anti-cancer therapies in 2006 from the University of Barcelona in Barcelona, Spain.

Dr. Ashok Srivastava, M.D., Ph.D., MBA, is the Chief Medical Officer, Senior Vice President Immuno-Oncology, Medical Oncology and Hematology Drug Development, Medical Affairs and Pharmacovigilance for CliniFomatrix. He is also the current Medical Advisor-Vice President of Medical Affairs for Taiho Oncology Inc. Previously he held positions as the Vice President of Oncology Drug Development, Medical Affairs and Clinical Operations for Spectrum Pharmaceuticals, as well as the Executive Medical Director for the Global Oncology Business Unit, Lead Oncology, Global Medical Affairs Oncology for Eisai, Inc. He has more than 15 years of experience in drug development, medical affairs and commercialization of cancer drugs including radiopharmaceutical and supportive care; Phase I - 4, and marketing commercialization of Hematology, Oncology and radio-immuno-oncology drugs in the USA, EU and Japan. He is a pioneer in cancer drug development worldwide for large and complex Phase 3 Clinical Trials. Dr. Srivastava is one of the inventors of the Japanese encephalitis vaccine (IXIARO). Dr. Srivastava has published more than 85 papers in National and International Journals, holds more than 120 abstracts, three book chapters and two patents. Amongst his multiple awards and commendations both nationally and internationally, he has been recognized by the United Nations, Ministry of Health, Japan, and Department of Army, Walter Reed Army Medical Center and Walter Reed Army Institute of Research, Washington D.C., USA.

Job Titles:

• Adjunct Professor at the Moores UCSD Cancer Center
• Advisory Board Member of the European Society for Translational Medicine
• President, Medical and Scientific Affairs

Boris Minev, M.D. is a highly accomplished physician-scientist with extensive industrial and academic experience in Immuno-Oncology, oncolytic viruses and stem cell biology and applications. He has a significant track record in tumor immunology and cancer vaccine development, having worked closely on the development of the first cancer vaccine to be approved by a regulatory body (Melacine). Dr. Minev has also extensive expertise in immunotherapy clinical trial designs, logistics, and regulatory issues. He has a considerable supervision & management experience in industrial and academic settings and has excellent skills in biotech business development, communication, and collaboration. Previously he held a position as the Director of Immunotherapy and Translational Oncology at Genelux Corporation, where he was directing several preclinical and translational projects on oncolytic virotherapy, immunotherapy, and nanotechnology. Dr. Minev is also an adjunct professor at the Moores UCSD Cancer Center. There, he served previously as Principal Investigator and Director, Laboratory of Tumor Immunology and Immunotherapy where, for more than 15 years, his research has been focused on the discovery of new target antigens for immunotherapy of cancer and the development of optimized cancer vaccines. Prior to that, Dr. Minev worked in Dr. Steven Rosenberg's Tumor Immunology Section at the Surgery Branch of the National Cancer Institute. Dr. Minev is an Advisory Board Member of the European Society for Translational Medicine (EUSTM). He is a member of the Scientific and Clinical Advisory Boards of several biotechnology companies and has been an advisor for Amgen, Johnson & Johnson, Geron Corporation, McKinsey Consulting and Thomson Current Drugs, among others. He is the recipient of the European Association of Cancer Research Fellowship and the Fogarty International Fellowship.

Job Titles:

• Chairman of the Nominating and Corporate Governance Committee
• Member of the Board
• Member / Committee Chair
• President of DGL Advisors

David LaPré (Mr. LaPré), is an accomplished biopharmaceutical executive who previously served as EVP/Head of Global Pharma Technical Operations and VP of Global Supply Chain Management in Roche, Head of Global Operations in Roche Diagnostics and VP, Technical Operations North America of Roche/Genentech, etc., with significant global management experience in the production, manufacture, and commercial listing and supply of medicines. Mr. LaPré is currently President of DGL Advisors, LLC, a consultancy focused on advising leaders in the bio-pharma industry on strategy, leadership effectiveness, capability building and post-merger integration. He has assisted numerous companies in their efforts to enhance productivity, improve supply-reliably/quality and ensure the timely commercialization of new molecules. He also currently serves on a number of corporate and university Boards as well as advisory boards for global biopharmaceutical companies.

Dmitriy Zamarin, M.D., Ph.D., is the Medical Oncologist, Gynecologic Medical Oncology and Immunotherapeutics for Memorial Sloan Kettering Cancer Center. Previously he held positions as Research Fellow and Hematology/Oncology Fellow for Memorial Sloan Kettering Cancer Center. Zamarin is a medical oncologist specializing in the care of women with gynecologic cancers, including cervical, ovarian, and endometrial cancers. His research is focused on the development of genetically engineered oncolytic viruses, an emerging class of immune therapeutic drugs that have shown significant clinical promise in the recent years. By manipulating the oncolytic viruses and the immune system, Zamarin is exploring different ways to enhance the immune recognition of tumors and to develop novel treatment strategies that would be applicable to different cancer types. Dr. Zamarin received his M.D. degree from Mount Sinai School of Medicine of New York University. Amongst his multiple awards and commendations both nationally and internationally, he was awarded the 2014 Bladder Cancer Awareness Network Young Investigator, the 2013 Conquer Cancer Foundation ASCO Young Investigator Award, Damon Runyon Foundation Fellowship Award, and the 2012 Celgene Future Leaders in Hematology Award.

Job Titles:

• Scientist
• Associate Vice President, Manufacturing Operations

Dr. Barbara Haertl is an experienced scientist who specializes in process development and manufacturing in the field of oncolytic viral therapy. Barbara has more than 12 years of industry experience that spans oncolytic virotherapy, translational oncology, and biological drug development. She joined StemVAC GmbH/Calidi Biotherapeutics in 2016 and has focused on Vaccinia Virus-based process development and manufacturing activities for virus, cell, and combination products. Prior to joining StemVAC GmbH, Barbara led translational product development studies for oncolytic virus cancer theranostics at Genelux GmbH - a clinical-stage oncolytic virus therapy company. Dr. Haertl received her Ph.D. in Virology on studying Adenovirus from the University of Regensburg, Department for Medical Microbiology and Hygiene, Germany

Job Titles:

• Michael J. Marchese Professor and Chairman

Dr. Maciej (Matt) Lesniak is the Michael J. Marchese Professor and Chairman, Department of Neurological Surgery, at Northwestern University Feinberg School of Medicine in Chicago. He is also the Program Leader in Neuro-Oncology at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Prior to his current position, he was a Professor of Neurosurgery, Neurology, and Cancer Biology at the University of Chicago and Director of Neurosurgical Oncology and the Neuro-Oncology Research Laboratories at the University of Chicago Hospitals and the Pritzker School of Medicine. He is a graduate of Harvard University and the Johns Hopkins University School of Medicine. In addition, he has a Master's degree in Health Care Management from Harvard. Dr. Lesniak completed his neurosurgical and neuro-oncology training at Johns Hopkins under Drs. Donlin Long, Henry Brem, and Drew M. Pardoll. His research interests focus on novel targeted therapies for human gliomas, including gene therapy, stem cell biology, immunotherapy, and nanotechnology. He has been overall PI or site PI of over 25 multi-institutional clinical trials for recurrent and newly diagnosed malignant gliomas involving these biological therapies and his research has been continually supported by the National Institutes of Health, the American Cancer Society, and the Alliance for Cancer Gene Therapy. He is the recipient of the prestigious Outstanding Young Investigator Award from the American Society of Gene and Cell Therapy. He has successfully mentored numerous scientists into independent academic positions in the US and abroad and several of his current trainees are supported by NIH awards. In recognition of his contributions to the Pritzker School of Medicine at the University of Chicago, he was awarded the John D. Arnold Scientific Research Prize for sustained excellence in mentoring medical students. Dr. Lesniak maintains a busy neurosurgical practice primarily dedicated to patients with brain cancer, with a focus on primary and malignant tumors of the central nervous sytem. In 2015, he was awarded the National Cancer Institute Outstanding Investigator Award, given to 50 scientists in the United States for transformative cancer research. He is the principal investigator of the Northwestern Brain Tumor SPORE, an NCI translational research program focusing on innovative therapeutics in brain cancer.

Job Titles:

• Associate Vice President, R & D, Process & Assay Development
• Professional Scientist

Dr. Thomas Herrmann is a professional scientist with more than 16 years of experience in the development of cellular manufacturing processes and companion analytics. He holds a PhD in Biochemistry from the University of Wuerzburg, Germany. Dr. Herrmann joined StemVAC GmbH/Calidi Biotherapeutics in 2016 and has dedicated his scientific career to the research and engineering of manufacturing processes and assay development for oncolytic viruses, stem cells, and cellular combination products. Before joining StemVAC GmbH, Thomas specialized in the investigation of new recombinant oncolytic vaccinia viruses and radiotracers for application in molecular PET diagnostics of tumors at Genelux GmbH, a clinical-stage oncolytic virus therapy company. Prior to StemVAC, Thomas worked as group leader for the Department of Clinical Neurobiology at the University Clinics of Wuerzburg, contributing greatly to the field of therapeutic application for spinal muscular atrophy with lentiviral vectors.

Job Titles:

• Executive Director of Clinical Development for FibroGen, Inc

Ewa Carrier, M.D. is the Executive Director of Clinical Development for FibroGen, Inc. Previously she held positions as the Director of Clinical Development and Medical Affairs for Boehringer Ingelheim, and as the Vice President of Medical Affairs at NovaRx Corporation, where she was a principal investigator and co-investigator for clinical protocols. Dr. Carrier is a distinguished leader and innovator in the field of cancer diagnosis and treatment. She served as an Associate Professor of Clinical Medicine and Pediatrics in the blood and marrow transplant program at the University of California, San Diego School of Medicine. Dr. Carrier has board certifications in Pediatrics and Pediatric Hematology/Oncology.

Job Titles:

• Member of the Board
• Partner at PENG Life Science Ventures

George Ng, a partner at PENG Life Science Ventures and veteran biotech executive, has been a member of Calidi's Board of Directors since October 2019. His significant experience includes serving in various executive-level positions for multiple publicly-traded and private global biotechnology and pharmaceutical firms-including BioDelivery Sciences International, Inc., Spectrum Pharmaceuticals, Inc., Sorrento Therapeutics, Inc., and Alpharma, Inc., now part of Pfizer, Inc. Throughout these roles, Ng has contributed his expertise to the launches and commercialization efforts of multiple pharmaceutical drug products, co-founding and leading one pain medication company from preclinical to clinical research, through NDA submission, FDA approval, commercialization, and the subsequent sale of the business-raising over $140 million in non-dilutive commercialization funding in the process. Early in his career, Ng worked as a partner in private practice at two law firms named to the Am Law 200 Report. He holds a JD degree from the University of Notre Dame School of Law, as well as a BAS double degree in Biochemistry and Economics from the University of California, Davis.

Job Titles:

• Member of the Nominating and Corporate Governance Committee
• Board Member - Appointed July 2020
• Member of the Board at Fibrogen, Inc

In addition to joining Calidi's Board of Directors in July 2020, James A. "Jim" Schoeneck has been a member of the Board at Fibrogen, Inc. since April 2010, currently serving as Chairman of the Board and as Interim CEO in 2019 and 2020. Prior, he joined the Board of Depomed, Inc. in 2007, then served as CEO from 2011 to 2017, leading the transformation into a commercial specialty pharmaceutical company. From 2005 until 2011, he was CEO of BrainCells Inc., a privately-held biopharmaceutical company. Before joining BrainCells, Inc., Schoeneck served as CEO of ActivX BioSciences, a development-stage biotechnology company. His diverse biotech experience further includes three years as President and CEO of Prometheus Laboratories Inc., a pharmaceutical and diagnostics product company, as well as three years as Vice President and General Manager, Immunology, at Centocor, Inc.-now Janssen Biotech, Inc. At Centocor, Schoeneck led the development of the biotechnology company's commercial capabilities and oversaw the launch of Remicade®, which became one of the world's largest pharmaceutical brands. Earlier in his career, he spent 13 years at pharmaceutical company Rhone-Poulenc Rorer, Inc.-now Sanofi-serving in various sales and marketing positions of increasing responsibility. Schoeneck holds a BS in Education from Jacksonville State University.

Karen Aboody received her MD at Mount Sinai School of Medicine, and completed her post-doctoral training in Molecular Neurogenetics at Massachusetts General Hospital, Harvard Medical School. She currently heads a translational stem cell-oncology laboratory at the City of Hope, focused on using tumor-tropic stem cells as delivery vehicles to target therapeutic agents to invasive and metastatic solid tumors, including brain tumors. In 2010, she received FDA approval for a first-in-human clinical safety trial for neural stem cell (NSC)-mediated enzyme/prodrug therapy for patients with recurrent high-grade glioma. She also received an $18MM CIRM Disease Team Award in 2010 to bring a second generation NSC-mediated therapeutic product to clinical trial for brain tumors by 2014. Recently, she received an NIH U-01 to translate this NSC-mediated approach for the treatment of metastatic neuroblastoma. Dr. Aboody received the AANS Young Investigator award in 2000, and the ASGT Outstanding New Investigator Award in 2008. In 2011, she founded TheraBiologics Inc., a clinical stage biopharmaceutical company, to support clinical development of NSC-mediated cancer therapies.

Job Titles:

• Co - Director

He was co-director (1999-2015) of the MDACC Brain Tumor Center, which he expanded with co-director Raymond Sawaya, M.D. Dr.

Santosh Kesari, M.D., Ph.D., serves as Director of Neuro-oncology and chair of the Department of Translational Neurosciences and Neurotherapeutics at John Wayne Cancer Institute at Providence Saint John's Health Center. He is also founder and director of Pacific Neuroscience Institute's Research Center. His research is focused on personalized medicine for patients with malignant brain tumors. He has extensive experience in precision therapeutic strategies targeting brain tumors. Dr. Kesari's research efforts have focused on oncolytic viruses, signal transduction, immunotherapy and translational clinical trials. Dr. Kesari received his M.D. and Ph.D. degrees in molecular biology from the University of Pennsylvania, School of Medicine. He has published more than 300 original articles, reviews, editorials, books and clinical communications. Dr. Kesari has received numerous awards and recognition throughout his medical career, and was named one of America's Top Doctors by Castle Connolly.

Job Titles:

• Member of the Nominating and Corporate Governance Committee
• Calidi 's Board of Directors As Vice - Chairman
• Vice - Chairman of the Board - Appointed May 2019

Scott Leftwich joined Calidi's Board of Directors as Vice-Chairman in May 2019. Previously, he owned a consulting company that personally advised a Group President of the Hospital Corporation of America (HCA) on the Fortune 100 company's care management strategy. From 2011 to 2014, Leftwich served as CEO at InterMedHx, a healthcare software company, since acquired by the world's second-largest electronic medical record company: Cerner Corporation. Between 2005 and 2010, he held the position of COO at Anakam, a security software company-acquired by Equifax in 2010-focused on the protection of personal healthcare information within patient-facing portals. Prior, he was COO of an education company, which he successfully grew from 150 to 800 employees, as well as from $10 million to over $60 million in revenues in under four years. Leftwich spent the first 15 years of his career as a P-3 pilot in the Navy, where he rose to the rank of Commander, flying across the world for missions in Iceland, the United Kingdom, Japan, Korea, Sicily, and South America. His final assignment in the service was to lead one of the nation's most sensitive presidential contingency programs at the White House Military Office. Leftwich holds an MBA with honors from Harvard Business School, in addition to a BS with distinction from the US Naval Academy.

Job Titles:

• Investor Contact

Job Titles:

• Chief Business Officer

Stephen Thesing serves as Chief Business Officer, a position he has held since 2021. In this role, Stephen has led the company's Series B financing and public listing activities and secured strategic biopharma collaboration agreements and licensing agreements on the company's behalf. Stephen joined Calidi in 2016 and previously served as Chief Operations Officer, Chief Administrative Officer, and Senior Vice President of Corporate Development and Operations, during this time he oversaw the integration of Calidi subsidiary StemVac GmbH into the company. Stephen has extensive experience in strategic licensing and dealmaking having served in several high-growth companies across multiple industries prior to joining Calidi. Stephen served as Vice President of Business Development and Marketing for HiPaaS Inc., a software technology provider and systems integrator for Healthcare Payers, where he closed revenue deals with several large payers and cultivated valuable strategic partnerships with Dell-Boomi, and Qlik. He also held executive level business development roles at several startups including Civica Software (acquired by Granicus), Parametric Sound (acquired by Turtle Beach Corp), Anakam (acquired by Equifax), Dot Hill Systems, and Troika Networks (acquired by Qlogic). Mr. Thesing received a Bachelor of Science in Business, Information Systems, and Marketing from California Polytechnic University, San Luis Obispo.

Job Titles:

• Professor of Neuro - Oncology at the University of Texas MD Anderson Cancer Center

Dr. Yung is professor of Neuro-oncology at The University of Texas MD Anderson Cancer Center, where he held the Margaret and Ben Love Chair of Clinical Cancer Care and dual appointment as professor of Cancer Biology. He is also a faculty member at the UT Graduate School of Biomedical Sciences in Houston. He earned his undergraduate degree from the University of Minnesota, Minneapolis and his medical degree from the University of Chicago Pritzker School of Medicine. Internship and residency training followed at the University of California, San Diego. He completed chief residency and a fellowship at Cornell University School of Medicine and Memorial Sloan-Kettering Cancer Center. Dr. Yung joined MD Anderson as assistant professor in 1981 and rose quickly through the faculty ranks. Yung has led the department of Neuro-Oncology as ad interim chair (1999-2002) and as chair (2002-2015). During his tenure, the department has expanded to 24 faculty who have achieved much under his guidance, including development of a National Cancer Institute (NCI)-funded Brain Tumor Clinical Trial Consortium, a Brain Specialized Program of Research Excellence (SPORE), and the groundbreaking D24 smart oncolytic virus program. Dr. Yung's extensive experience and expertise in brain tumor research has included more than three decades of basic, translational and clinical studies at MD Anderson. Published more than 350 peer-reviewed journals, his research aims to develop new therapeutic approaches to block the regulatory mechanisms of brain cancer cells. His primary focus is on development of molecular therapeutic strategies targeting the EGFR and PTEN/PI3 kinase pathways and tumor resistant mechanisms that are crucial to the progression of human glioma. Dr. Yung's many significant contributions to his field include discovery of the PTEN gene with Peter Steck; leading the study that led to FDA approval of temozolomide for glioblastoma and co-leadership of the registration study which led to approval of the drug bevacizumab for recurrent glioblastoma; development and funding of the National Cancer Institute (NCI)-funded Brain Tumor SPORE; building of the D24 smart oncolytic virus program; leadership in the NCI- funded CNS tumor clinical trial consortia and creation of the GBM Agile, a global adaptive clinical trial platform. Dr. Yung served as Editor-in-Chief of Neuro-Oncology (2007-2014), and co-chair of the NCI Brain Malignancy Steering Committee (2011-2017). He was appointed to Vice President Biden's Cancer Moonshot Blue Ribbon Panel in 2016. He is currently serving as Special Scientific Advisor of National Brain Tumor Society (NBTS), Chair of SAB for Asia Foundation for Cancer Research (AFCR), member of SAC for Ludwig Institute of Cancer Research (LICR), member of SAB for DNATrix, ILCT Inc, Quadriga, Denovo Biopharm, and a member of the MDACC Cancer Moonshot Leadership Committee.

Job Titles:

• Chief Administrative Officer
• Chief Legal Officer
• Fellow at Harvard University

Wendy Pizarro, Esq. has served as Calidi's Chief Legal Officer and Chief Diversity Officer since September 2021. Honored as one of the "Power Women of San Diego" by Discover Magazine, Wendy is a role model for women as a seasoned corporate attorney and digital health advocate. Wendy joined the executive leadership team, because she is passionate about the vision of Calidi and finding an innovative cure for cancer. In her combined role at Calidi, she is responsible for the Company's global legal strategy and implementation, which includes overseeing all legal matters across corporate governance, securities and compliance; regulatory issues; licensing and intellectual property strategy; patent portfolio protection; employment; corporate transactions; and litigation. Furthermore, Wendy is the Company's lead in shaping external and internal policies in recruitment and marketing related to furthering principles of diversity, equity and inclusion in the Company's strategic plan. Wendy also serves as Calidi's Corporate Secretary. Wendy has over 20+ years of experience in corporate and business law, and since 2010, she founded and has led California Law Partners, a boutique law firm primarily serving as outside general counsel, corporate counsel and the lead crisis manager to select high net worth multi-family offices. She has directed legal strategy related to risk management, compliance and operations to manage and grow an asset portfolio of over $1.5 billion in multi-generational wealth with over 60% of the portfolio in private investments, some of which include Calidi. Previously, she worked with leading Silicon Valley law firms, including DLA Piper in Palo Alto, on numerous general corporate and intellectual property matters and corporate securities transactions for disruptive technology companies in all phases of their life cycles from start-up to liquidity event (IPO and M&A) primarily in small teams serving infrastructure and e-commerce, including McAfee, Applied Materials and Yahoo!. Wendy is also an active tech investor in start-ups or early-stage funds related to digital health, preventative medicine, life sciences, and digital media. Most recently, as a co-founder and investor of Never Train Alone, she designed the software user interface for an Apple iOS app related to mobile fitness, corporate wellness and preventative health. Wendy continues to be active as a community leader and volunteer and has served on non-profit boards, for example, working with Rady Children's Hospital Auxiliary as a unit officer, board member and/or lifetime member. A former teaching fellow at Harvard University, Wendy was awarded the Derek Bok Award for Excellence in Teaching. She has been asked to conduct legal seminars or be a guest speaker at numerous events throughout her career and has authored eBooks, legal kits and other media in different areas of law, including start-up and corporate matters. Wendy holds a J.D. from the Harvard Law School, M.ST. from the University of Oxford, and M.A. and B.A. from Yale University graduating magna cum laude with honors in distinction. She is proficient in Spanish, Italian and Tagalog. Wendy is a member of the State Bar of California and U.S. District Court, Southern District of California.